Premium
A placebo‐controlled dose response study of the reactogenicity and immunogenicity of a live cold‐recombinant influenza B virus vaccine in healthy volunteers
Author(s) -
Ganzinger U.,
Bachmayer H.,
Liehl E.,
Martindale J. J.,
Hamilton F.,
Kuwert E. K.
Publication year - 1988
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890250211
Subject(s) - reactogenicity , immunogenicity , virology , virus , recombinant dna , influenza vaccine , medicine , live attenuated influenza vaccine , biology , immunology , antibody , gene , biochemistry
A live cold‐recombinant influenza B virus vaccine (RB77) was given intranasally in a placebo‐controlled, double blind study to volunteers in dosages of 10 7.9 EID 50 /ml, 10 7.25 EID 50 /ml, 10 5.7 EID 50 /ml. The tolerability, safety, and immunogenicity of the vaccine were investigated. No revertant virus was found in nasal swabs taken after immunisation. Local reactions were mild and showed a significant increase over the placebo only in the highest dose group. Systemic reactions were not different from the placebo. A significant increase in haemagglutinin inhibition titre was found in the highest dose group against the immunising strain (RB77) and the two wild strains B/TEC and B/Sing.